Antiobesity action of a daidzein derivative on male obese mice induced by a high-fat diet

Emerging evidence suggests that consumption or supplementation of foods rich in isoflavones may has a beneficial effect on obesity and glucose levels in animals and humans. It has been demonstrated that genistein, the main component of isoflavones, could significantly reduce body weight and fat pad size. However, there is no evidence as to whether daidzein, which is also a main component of isoflavones, has the same effect. We hypothesize that LRXH609 (Dzd; a daidzein derivative) also has an antiobesity effect. In this study, we investigate the effects of Dzd on body weight, adipose tissue, blood, and liver lipid levels in obese mice fed a high-fat diet. Activities of pancreatic lipase and lipoprotein lipase, as well as lipolysis, were verified to clarify the potential mechanism of the daidzein. The results indicate that Dzd can significantly reduce body and fat pad weight and ameliorate the high-fat diet–induced hyperlipoidemia. We also found that Dzd inhibits the activity of pancreatic lipase and lipoprotein lipase in a dose-dependent manner, inhibits the differentiation of rat preadipocytes, and stimulates lipolysis by activating hormone-sensitive lipase.